CARMIEL, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that senior management will present at three upcoming healthcare conferences. Details regarding the conferences are as follows:
Jefferies 2013 Global Healthcare Conference
Monday, June 3, 2013 at 3:30 PM ET
The Grand Hyatt, New York, NY
ILSI-Biomed 2013 Conference
Wednesday, June 12, 2013 at 3:10 PM IDT
David Intercontinental Hotel, Tel-Aviv, Israel
Wells Fargo Securities Research & Economics 2013 Healthcare Conference
Wednesday, June 19, 2013 at 2:25 PM ET
The Boston Intercontinental Hotel, Boston, MA
A live webcast of the presentation at each of the Jefferies 2013 Global Healthcare Conference and the Wells Fargo Securities Research & Economics 2013 Healthcare Conference will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the respective conference for 30 days.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.
CONTACT: Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 email@example.com Media Contact Kari Watson MacDougall Biomedical Communications 781-235-3060 firstname.lastname@example.orgSource:Protalix BioTherapeutics, Inc.